Evidence map›Paper›PMID 37370922›Full record

ArticleDiagnostics (Basel, Switzerland)2023

Analysis of Positive Results of

Na Dai, Rongcui Cai, Shengming Deng, Shibiao Sang

Open access · goldAbstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 77% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Na DaiDepartment of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.ORCID 0000-0003-1401-1547
Rongcui CaiDepartment of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Shengming DengDepartment of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.ORCID 0000-0002-1450-7721
Shibiao SangDepartment of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Soochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe purpose of this study was to differentiate between false-positive and true-positive positron emission tomography (PET) results after hematopoietic stem cell transplantation (SCT) for lymphoma involvement by analyzing several clinical variables and specific imaging features. PATIENTS AND

methodsPatients with lymphoma who received SCT and underwent post-transplantation

resultsA total of 185 patients (235 post-transplantation PET/CT scans) were enrolled in our present study. Compared with those with true-positive PET results, patients with false-positive PET results exhibited a better prognosis. For the autologous SCT group, false-positive cases were more commonly seen when FDG-avid foci appeared outside the sites of the original disease (

conclusionFalse-positive FDG uptake in post-transplantation PET was not uncommon. Several variables could provide an important reference to differentiate false-positive from true-positive post-SCT PET results for lymphoma involvement. TRIAL REGISTRATION NUMBER: ChiCTR2300067355.

Indexed as

Deauville scorefalse-positive FDG uptakelymphomapost-transplantation 18F-FDG PET/CTSCT

Identifiers

PMID37370922
PMCPMC10296960
OpenAlexW4380368272

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.